
1. EBioMedicine. 2021 Nov;73:103637. doi: 10.1016/j.ebiom.2021.103637. Epub 2021 Oct
19.

Release of infectious virus and cytokines in nasopharyngeal swabs from
individuals infected with non-alpha or alpha SARS-CoV-2 variants: an
observational retrospective study.

Monel B(1), Planas D(2), Grzelak L(3), Smith N(4), Robillard N(5), Staropoli
I(1), Goncalves P(6), Porrot F(1), Guivel-Benhassine F(1), Guinet ND(7), Rodary
J(5), Puech J(5), Euzen V(5), Bélec L(8), Orvoen G(9), Nunes L(10), Moulin V(10),
Fourgeaud J(11), Wack M(12), Imbeaud S(13), Campagne P(14), Duffy D(4), Santo
JPD(6), Bruel T(2), Péré H(13), Veyer D(15), Schwartz O(16).

Author information: 
(1)Virus & Immunity Unit, Department of Virology, Institut Pasteur, Paris,
France; CNRS UMR 3569, Paris, France.
(2)Virus & Immunity Unit, Department of Virology, Institut Pasteur, Paris,
France; CNRS UMR 3569, Paris, France; Vaccine Research Institute, Creteil,
France.
(3)Virus & Immunity Unit, Department of Virology, Institut Pasteur, Paris,
France; CNRS UMR 3569, Paris, France; Université de Paris, Sorbonne Paris Cité,
Paris, France.
(4)Translational Immunology Lab, Department of Immunology, Inserm U1223, Institut
Pasteur, Paris.
(5)Hôpital Européen Georges Pompidou, Laboratoire de Virologie, Service de
Microbiologie, Paris, France.
(6)Innate Immunity Unit, Department of Immunology, Department of Immunology,
Inserm U1223, Institut Pasteur, Paris; Inserm U1223, Paris, France.
(7)Hôpital Européen Georges Pompidou, Service de Médecine du Travail, Paris,
France.
(8)Hôpital Européen Georges Pompidou, Laboratoire de Virologie, Service de
Microbiologie, Paris, France; Hôpital européen Georges Pompidou INSERM U970,
PARCC, Faculté de Médecine, Université de Paris, Paris, France.
(9)Hôpital Vaugirard, Service de gériatrie, Assistance Publique-Hôpitaux de
Paris, Paris, France.
(10)Hôpital Corentin Celton, Service de gériatrie, Assistance Publique-Hôpitaux
de Paris, Issy-les-Moulineaux, France.
(11)Université de Paris, EHU 7328 PACT, Institut Imagine, Paris, France; Virology
Department, AP-HP, Necker Enfants Malades Hospital, Paris, France.
(12)Hôpital Européen Georges Pompidou, Département d'Informatique Médicale,
Biostatistiques et Santé Publique.
(13)INSERM, Functional Genomics of Solid Tumors (FunGeST), Centre de Recherche
des Cordeliers, Université de Paris and Sorbonne Université, Paris, France.
(14)Bioinformatic and Biostatistic Hub, Institut Pasteur, Paris.
(15)Hôpital Européen Georges Pompidou, Laboratoire de Virologie, Service de
Microbiologie, Paris, France; INSERM, Functional Genomics of Solid Tumors
(FunGeST), Centre de Recherche des Cordeliers, Université de Paris and Sorbonne
Université, Paris, France.
(16)Virus & Immunity Unit, Department of Virology, Institut Pasteur, Paris,
France; CNRS UMR 3569, Paris, France; Vaccine Research Institute, Creteil,
France. Electronic address: olivier.schwartz@pasteur.fr.

BACKGROUND: The dynamics of SARS-CoV-2 alpha variant shedding and immune
responses at the nasal mucosa remain poorly characterised.
METHODS: We measured infectious viral release, antibodies and cytokines in 426
PCR+ nasopharyngeal swabs from individuals harboring non-alpha or alpha variants.
FINDINGS: With both lineages, viral titers were variable, ranging from 0 to
>106 infectious units. Rapid antigenic diagnostic tests were positive in 94% of
samples with infectious virus. 68 % of individuals carried infectious virus
within two days after onset of symptoms. This proportion decreased overtime.
Viable virus was detected up to 14 days. Samples containing anti-spike IgG or IgA
did not generally harbor infectious virus. Ct values were slightly but not
significantly lower with alpha. This variant was characterized by a fast decrease
of infectivity overtime and a marked release of 13 cytokines (including IFN-b,
IP-10 and IL-10).
INTERPRETATION: The alpha variant displays modified viral decay and cytokine
profiles at the nasopharyngeal mucosae during symptomatic infection.
FUNDING: This retrospective study has been funded by Institut Pasteur, ANRS,
Vaccine Research Institute, Labex IBEID, ANR/FRM and IDISCOVR, Fondation pour la 
Recherche Médicale.

Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.

DOI: 10.1016/j.ebiom.2021.103637 
PMCID: PMC8526063
PMID: 34678613 

Conflict of interest statement: Declaration of Competing Interest L.G., I.S.,
T.B., F.G.-B., and O.S. have a patent US 63/020,063 entitled “S-Flow: a
FACS-based assay for serological analysis of SARS-CoV2 infection” pending. The
other authors have no conflict of interests to disclose.

